United States securities and exchange commission logo

                          December 1, 2020

       N. Anthony Coles, M.D.
       President and Chief Executive Officer
       Cerevel Therapeutics Holdings, Inc.
       222 Jacobs Street, Suite 200
       Cambridge, MA 02141

                                                        Re: Cerevel
Therapeutics Holdings, Inc.
Statement on Form S-1
                                                            Filed November 25,
                                                            File No. 333-250964

       Dear Mr. Coles:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact David
Gessert at 202-551-2326 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences